Standard BioTools Inc. (LAB)

NASDAQ: LAB · Real-Time Price · USD

0.6419

-0.0111 (-1.70%)

At close: Aug 28, 2026, 4:00 PM EDT

0.6548

+0.0129 (2.01%)

After-hours: Aug 28, 2026, 7:30 PM EDT

-1.70% (1D)

Market Cap	252.00M -48.5%
Revenue (ttm)	84.60M -4.8%
Net Income	84.91M
EPS	0.22
Shares Out	392.58M
PE Ratio	2.97
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,260,472
Open	0.6550
Previous Close	0.6530
Day's Range	0.6370 - 0.6699
52-Week Range	0.6251 - 1.7200
Beta	1.40
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 5, 2026

About LAB

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneo... [Read more]

Industry Medical Devices

Sector Healthcare

IPO Date Feb 10, 2011

Employees 389

Stock Exchange NASDAQ

Ticker Symbol LAB

Website https://www.standardbio.com

Full Company Profile

Financial Performance

In 2025, Standard BioTools's revenue was $85.33 million, a decrease of -6.24% compared to the previous year's $91.01 million. Losses were -$74.90 million, -59.49% less than in 2024.

Financial Statements

News

Standard BioTools Reports Second Quarter 2026 Financial Results

BOSTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended June 30, 2026.

24 days ago - GlobeNewsWire

Standard BioTools Earnings release: Q2 2026

Standard BioTools released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.

24 days ago - Filings

Standard BioTools Quarterly report: Q2 2026

Standard BioTools has published its Q2 2026 quarterly earnings report on August 5, 2026.

24 days ago - Filings

Standard BioTools to sell Mass Cytometry business to Multiplex Bio for $10M

Standard BioTools (LAB) announced the following updates in connection with the company’s previously announced merger with Treeline Biosciences. Agreement to sell its Mass Cytometry business to Multipl...

Other symbols: ILMN

4 weeks ago - TheFly

Standard BioTools Announces Sale of Mass Cytometry Business and Illumina's Buyout of Contingent Payments to Advance Merger with Treeline Biosciences

Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation Multipl...

4 weeks ago - GlobeNewsWire

Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026

BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its second quarter 2026 financial results on Wednesday, August 5, 2026, after...

5 weeks ago - GlobeNewsWire

Standard BioTools files registration statement for Treeline Biosciences merger

Standard BioTools (LAB) announced the filing of a registration statement on Form S-4 with the SEC in connection with its previously announced definitive merger agreement with Treeline Biosciences. Upo...

5 weeks ago - TheFly

Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction

Highlights combined company's strong financial position with over $900 million expected at closing, Treeline's deep clinical-stage pipeline, planned 2027 data updates for TLN-121 and TLN-372, and expe...

5 weeks ago - GlobeNewsWire

Standard BioTools Transcript: AGM 2026

The meeting covered director elections, executive compensation, auditor ratification, and equity plan approvals, with all proposals passing. No questions were submitted during the Q&A, and forward-looking risks were highlighted.

2 months ago - Transcripts

LiveRamp Launches Agentic Partner Program to Fast-Track Agentic Deployments for Customers

SAN FRANCISCO--(BUSINESS WIRE)--LiveRamp (NYSE: RAMP), the leader in data collaboration, today announced LiveRamp Agent Builders (LAB), a new program to bring more partner-built agents into its networ...

Other symbols: RAMP

2 months ago - Business Wire

Labrador Gold to Host Investor Webinar on the Mariposa Gold Project in Yukon's White Gold District

TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Labrador Gold Corp. (TSX Venture: LAB) ("Labrador Gold" or the "Company") is pleased to announce that it will host a live investor webinar on Wednesday, June...

2 months ago - GlobeNewsWire

Labrador Gold Announces 2026 Exploration Plans for Pacific Ridge's White Gold Projects

Vancouver, British Columbia--(Newsfile Corp. - June 11, 2026) - Pacific Ridge Exploration Ltd. (TSXV: PEX) (OTCQB: PEXZF) (FSE: PQW) ("Pacific Ridge" or the "Company") is pleased to report that Labrad...

2 months ago - Newsfile Corp

Standard BioTools, Treeline Biosciences to combine in all-stock transaction

Standard BioTools (LAB) and Treeline Biosciences announced they have entered into a definitive merger agreement to combine in an all-stock transaction. Upon completion of the transaction, which is exp...

Other symbols: ILMN

2 months ago - TheFly

Standard BioTools and Treeline Biosciences Announce Merger Agreement

Combined company to operate as Treeline Biosciences, advancing a deep pipeline of small molecule inhibitors, protein degraders and targeted therapy antibody-drug conjugates

2 months ago - GlobeNewsWire

Standard BioTools Transcript: M&A announcement

The merger creates a well-capitalized precision medicine company with a diverse clinical pipeline and experienced leadership. The all-stock deal, expected to close in 2H 2026, positions the combined entity for accelerated value creation and long-term growth.